Home/Filings/4/0001415889-24-008771
4//SEC Filing

Gillies Hunter 4

Accession 0001415889-24-008771

CIK 0001798749other

Filed

Mar 19, 8:00 PM ET

Accepted

Mar 20, 6:00 PM ET

Size

14.9 KB

Accession

0001415889-24-008771

Insider Transaction Report

Form 4
Period: 2024-03-18
Gillies Hunter
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-03-18$1.74/sh+4,000$6,9607,251 total
  • Exercise/Conversion

    Common Stock

    2024-03-18$2.14/sh+3,000$6,42010,251 total
  • Sale

    Common Stock

    2024-03-18$25.81/sh6,387$164,8723,864 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-03-183,00098,510 total
    Exercise: $2.14Exp: 2031-04-01Common Stock (3,000 underlying)
  • Sale

    Common Stock

    2024-03-18$26.40/sh613$16,1853,251 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2024-03-184,0004,036 total
    Exercise: $1.74Exp: 2030-09-03Common Stock (4,000 underlying)
Footnotes (5)
  • [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  • [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  • [F4]A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
  • [F5]A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.

Issuer

Aerovate Therapeutics, Inc.

CIK 0001798749

Entity typeother

Related Parties

1
  • filerCIK 0001868997

Filing Metadata

Form type
4
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 6:00 PM ET
Size
14.9 KB